The primary sclerosing cholangitis market comprises drugs and treatments to manage the symptoms of primary sclerosing cholangitis, a rare disorder that causes inflammation and scarring in the bile ducts of the liver. Primary sclerosing cholangitis (PSC) is a rare long-term disease that causes narrowing and scarring of the bile ducts inside and outside the liver. Patients with PSC experience itching, jaundice, abdominal pain, fatigue, weight loss, and fever as the disease progresses. The increasing research funding for orphan and rare disease drug development coupled with innovations in drug therapies and drug delivery mechanisms are driving the growth of the primary sclerosing cholangitis market. However, limited disease awareness and lack of treatment options remain key challenges.

The Global primary sclerosing cholangitis Market is estimated to be valued at US$ 2.29 Mn in 2024 and is expected to exhibit a CAGR of 5.0% over the forecast period 2024 to 2030.

Key Takeaways

Key players operating in the Global Primary Sclerosing Cholangitis Market Size are Volkswagen Group, BMW Group, Mercedes-Benz (Daimler AG), Audi (Volkswagen Group), Ford Motor Company, General Motors, Toyota Motor Corporation, Honda Motor Co. Ltd., Hyundai Motor Group, Kia Motors Corporation, Nissan Motor Co. Ltd., Mazda Motor Corporation, Subaru Corporation, Volvo Cars, Peugeot SA. These companies are focusing on new drug development and drug delivery innovations to boost the treatment landscape for PSC.

The increasing research funding from government and nonprofit organizations presents opportunities for the development of novel treatment options for PSC. As per recent reports, the German government is allocating €38 million for innovative research in orphan and rare diseases for 2023. Similarly, in the US, National Organization for Rare Disorders (NORD) had provided a funding of $5.9 million to 34 different rare disease research projects in 2021.

The key players are expanding their global presence for PSC treatment through new product launches, which will propel the market growth. For instance, in 2022 Volkswagen Group expanded its PSC drug portfolio in Germany, the Nordic countries, and Benelux by launching two new oral drug formulations to improve patient compliance. Nissan Motor Co. Ltd. also received approval to market its ant proliferative injectable drug for PSC in Australia and several Southeast Asian countries.

Market Drivers:

The main driver is the increasing research and development investment by governments and pharmacy companies which has led to innovation in PSC treatment landscape. Major research is focused on development of gene and cell-based therapies, novel drug targets and techniques like siRNA to provide transformative treatment for PSC patients.

Market restraints:

However, the growth of primary sclerosing cholangitis market is likely to get restrained by the limited awareness about the disease among general population and physicians. The rarity of the disease poses challenges in patient diagnosis and lack of established treatment guidelines. High cost of innovative drug therapies and limited reimbursement policies also hinder the market growth to some extent.

Segment Analysis

Content: The Primary Sclerosing Cholangitis market is dominated by the diagnostic instruments sub segment. This is because early and accurate diagnosis plays a vital role in determining the treatment options for PSC patients. Diagnostic instruments such as Magnetic Resonance Cholangiopancreatography (MRCP) help physicians to identify morphological changes in bile ducts and rule out secondary causes of PSC. This helps doctors to accurately diagnose the condition at early stages. The drug therapy sub segment is also growing steadily due to launch of novel drugs that can potentially slow down the progression of the disease.

Global Analysis

The Primary Sclerosing Cholangitis market in North America, particularly the United States, is the dominant as well as the fastest growing regional market. This is attributed to high awareness about the condition, availability of advanced healthcare facilities, and presence of leading manufacturers. The market in the United States is driven by the increasing PSC patient pool and rising medical spending. Europe is also among the major markets for PSC due to growing research in this area. However, the Asia Pacific market is expected to show highest growth during the forecast period due to expanding healthcare infrastructure, rising medical tourism, and growing research funding in emerging countries.

Get More Insights Here

https://www.ukwebwire.com/primary-sclerosing-cholangitis-market-size-share-growth-outlook-2023/